Combination Transfer of αCD19-TCRz-41BB and αCD22-TCRz-41BB CAR-T Cells for B-cell Hematologic Malignancy

计划入组 20 人 · 首次发布于 2016 年 9 月 16 日

Immunotherapy Using 41BB Selected Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma

计划入组 6 人 · 首次发布于 2014 年 4 月 11 日

Infusion of PD1/PDL1/CTLA4 Inhibitors Via Hepatic Arterial for Immunotherapy of Hepatocellular Carcinoma

计划入组 200 人 · 首次发布于 2019 年 5 月 14 日

alphaCD19-TCRz-41BB + alphaCD22-TCRz-41BB

LAG3-PD1

PD1-F18

PDS Biotechnology

United States

PDC Biotech GmbH

Austria

PDC Brands S.A.

Guatemala

FDA Clears IND for Medigene's TCR-T Therapy MDG1015 in Advanced Solid Tumors

Medigene AG Refocuses Strategy on TCR-Guided Therapies, Pauses MDG1015 Trial

Medicenna Presents Preclinical Data on IL-2 Super-Antagonist MDNA209 and Anti-PD1-IL-2 BiSKIT MDNA113